Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
F
F
Ravandi
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
C
C
Arana Yi
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J E
JE
Cortes
Division of Hematological Malignancies, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, USA.
M
M
Levis
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
S
S
Faderl
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
G
G
Garcia-Manero
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
E
E
Jabbour
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
M
M
Konopleva
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
S
S
O'Brien
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Z
Z
Estrov
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
G
G
Borthakur
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
D
D
Thomas
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
S
S
Pierce
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
M
M
Brandt
Division of Hematological Malignancies, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, USA.
K
K
Pratz
Division of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
R
R
Luthra
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
M
M
Andreeff
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
H
H
Kantarjian
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives; D010671:Phenylurea Compounds / Q000008:administration & dosage; D000077157:Sorafenib; D016896:Treatment Outcome
D010671:Phenylurea Compounds; D003561:Cytarabine; D009536:Niacinamide; D000077157:Sorafenib; D015255:Idarubicin